# Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

> **NCT03334851** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 74 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Rheumatoid Arthritis

## Interventions

- **DRUG:** PF-06835375
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03334851
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-17
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334851, "Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03334851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*